Recommend. for the Management of hand-foot skin reaction
Posted: Mon Mar 22, 2010 8:52 am
Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
http://www.communityoncology.net/journa ... 701023.pdf
Multikinase inhibitors (MKIs, eg, sorafenib, sunitinib, cediranib etc) are oral anticancer agents associated with handfoot
skin reaction (HFSR), a cutaneous adverse event affecting 20%–40% of patients treated with these
drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened
duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently
provided the first consensus recommendations for the management of MKI-associated HFSR.
http://www.communityoncology.net/journa ... 701023.pdf
Multikinase inhibitors (MKIs, eg, sorafenib, sunitinib, cediranib etc) are oral anticancer agents associated with handfoot
skin reaction (HFSR), a cutaneous adverse event affecting 20%–40% of patients treated with these
drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened
duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently
provided the first consensus recommendations for the management of MKI-associated HFSR.